

# Shitij Kapur

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3463824/publications.pdf>

Version: 2024-02-01

311  
papers

39,401  
citations

2322

98  
h-index

2953

189  
g-index

319  
all docs

319  
docs citations

319  
times ranked

28131  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study. <i>Psychopharmacology</i> , 2022, 239, 3439-3445.   | 3.1  | 8         |
| 2  | Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). <i>Schizophrenia Bulletin</i> , 2021, 47, 505-516.  | 4.3  | 51        |
| 3  | Antipsychotics Circa 2020: What are we thinking?. <i>Neuropharmacology</i> , 2020, 175, 108181.  | 4.1  | 2         |
| 4  | The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2019, 85, 79-87.  | 1.3  | 54        |
| 5  | Small Sample Sizes and a False Economy for Psychiatric Clinical Trials. <i>JAMA Psychiatry</i> , 2019, 76, 676.  | 11.0 | 5         |
| 6  | Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. <i>Molecular Psychiatry</i> , 2019, 24, 1502-1512.   | 7.9  | 120       |
| 7  | Moment-to-moment associations between negative affect, aberrant salience, and paranoia. <i>Cognitive Neuropsychiatry</i> , 2018, 23, 299-306.  | 1.3  | 30        |
| 8  | Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018, 5, 797-807.  | 7.4  | 141       |
| 9  | Pharmacogenetics of antidepressant response: A polygenic approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 75, 128-134.  | 4.8  | 71        |
| 10 | Connectomic correlates of response to treatment in first-episode psychosis. <i>Brain</i> , 2017, 140, 487-496.   | 7.6  | 47        |
| 11 | The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life. <i>ELife</i> , 2017, 6, .  | 6.0  | 26        |
| 12 | Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. <i>Lancet Psychiatry</i> , 2016, 3, 1115-1128. | 7.4  | 59        |
| 13 | Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. <i>Journal of the Neurological Sciences</i> , 2016, 368, 243-248.   | 0.6  | 37        |
| 14 | The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Focus (American Journal of Psychiatry)</i> , 2016, 134, 1000-1008.   | 0.0  | 10        |
| 15 | Translating genome-wide association findings into new therapeutics for psychiatry. <i>Nature Neuroscience</i> , 2016, 19, 1392-1396.   | 14.8 | 115       |
| 16 | Initial depression severity and response to antidepressants <i>v.</i> placebo: patient-level data analysis from 34 randomised controlled trials. <i>British Journal of Psychiatry</i> , 2016, 209, 427-428.  | 2.8  | 52        |
| 17 | Dopamine, Striatum, Antipsychotics, and Questions About Weight Gain. <i>JAMA Psychiatry</i> , 2016, 73, 107.   | 11.0 | 12        |
| 18 | Phosphodiesterase 10A in Schizophrenia: A PET Study Using [ <sup>11</sup> C]IMA107. <i>American Journal of Psychiatry</i> , 2016, 173, 714-721.  | 7.2  | 33        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1381-1390.  | 2.2 | 11        |
| 20 | Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. <i>European Neuropsychopharmacology</i> , 2015, 25, 2098-2107.   | 0.7 | 77        |
| 21 | NEWMEDS special issue commentary. <i>Psychopharmacology</i> , 2015, 232, 3849-3851.   | 3.1 | 5         |
| 22 | Predicting clinical response in people at ultra-high risk of psychosis: a systematic and quantitative review. <i>Drug Discovery Today</i> , 2015, 20, 924-927.  | 6.4 | 9         |
| 23 | Longitudinal in vivo maturational changes of metabolites in the prefrontal cortex of rats exposed to polyinosinicâ€“polycytidylic acid in utero. <i>European Neuropsychopharmacology</i> , 2015, 25, 2210-2220.                           | 0.7 | 32        |
| 24 | Altered PDE10A expression detectable early before symptomatic onset in Huntingtonâ€™s disease. <i>Brain</i> , 2015, 138, 3016-3029.   | 7.6 | 90        |
| 25 | Re-examining the role of benzodiazepines in the treatment of schizophrenia: A systematic review. <i>Journal of Psychopharmacology</i> , 2015, 29, 212-223.  | 4.0 | 29        |
| 26 | The effects of a single dose of oxytocin on working memory in schizophrenia. <i>Schizophrenia Research</i> , 2015, 162, 62-63.  | 2.0 | 28        |
| 27 | Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance. <i>European Neuropsychopharmacology</i> , 2015, 25, 1578-1585.  | 0.7 | 5         |
| 28 | Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinsonâ€™s disease. <i>Brain</i> , 2015, 138, 3003-3015.   | 7.6 | 100       |
| 29 | Going Beyond "trial-and-error" in Psychiatric Treatments: OPTiMiSE-ing the Treatment of First Episode of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 546-548.  | 4.3 | 6         |
| 30 | Changes in delusional dimensions and emotions over eight weeks of antipsychotic treatment in acute patients. <i>Psychiatry Research</i> , 2015, 228, 393-398.   | 3.3 | 4         |
| 31 | Modafinil combined with cognitive training: Pharmacological augmentation of cognitive training in schizophrenia. <i>European Neuropsychopharmacology</i> , 2015, 25, 1178-1189.   | 0.7 | 50        |
| 32 | Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank: Figure 1.. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv042.   | 2.1 | 84        |
| 33 | The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Schizophrenia Bulletin</i> , 2015, 41, 549-558. | 4.3 | 47        |
| 34 | The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review. <i>Schizophrenia Bulletin</i> , 2015, 41, 559-573.  | 4.3 | 93        |
| 35 | Calibration and cross-validation of MCCB and CogState in schizophrenia. <i>Psychopharmacology</i> , 2015, 232, 3873-3882.   | 3.1 | 31        |
| 36 | Effects of haloperidol and aripiprazole on the human mesolimbic motivational system: A pharmacological fMRI study. <i>European Neuropsychopharmacology</i> , 2015, 25, 2252-2261.   | 0.7 | 8         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | UK Doubles Its "World-Leading" Research in Life Sciences and Medicine in Six Years: Testing the Claim?. PLoS ONE, 2015, 10, e0132990.   | 2.5  | 11        |
| 38 | Mobile early detection and connected intervention to coproduce better care in severe mental illness. Studies in Health Technology and Informatics, 2015, 216, 123-6.  | 0.3  | 6         |
| 39 | White matter integrity as a predictor of response to treatment in first episode psychosis. Brain, 2014, 137, 172-182.   | 7.6  | 130       |
| 40 | Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. British Journal of Psychiatry, 2014, 204, 420-429.  | 2.8  | 98        |
| 41 | How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses. European Neuropsychopharmacology, 2014, 24, 1279-1288.   | 0.7  | 13        |
| 42 | Dopaminergic Function in Cannabis Users and Its Relationship to Cannabis-Induced Psychotic Symptoms. Biological Psychiatry, 2014, 75, 470-478.  | 1.3  | 170       |
| 43 | The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology, 2014, 231, 2251-2259.   | 3.1  | 86        |
| 44 | CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature, 2014, 505, 361-366.   | 27.8 | 588       |
| 45 | Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. Journal of Nuclear Medicine, 2014, 55, 595-601.   | 5.0  | 50        |
| 46 | A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type B (normodopaminergic). British Journal of Psychiatry, 2014, 205, 1-3.   | 2.8  | 166       |
| 47 | Combining efficacy and completion rates with no data imputation: A composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trials. European Neuropsychopharmacology, 2014, 24, 357-368. | 0.7  | 2         |
| 48 | Changes in delusions in the early phase of antipsychotic treatment " An experience sampling study. Psychiatry Research, 2014, 215, 568-573.   | 3.3  | 42        |
| 49 | Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function. Biological Psychiatry, 2014, 75, e11-e13.   | 1.3  | 280       |
| 50 | Reduced Cortical Volume and Elevated Astrocyte Density in Rats Chronically Treated With Antipsychotic Drugs"Linking Magnetic Resonance Imaging Findings to Cellular Pathology. Biological Psychiatry, 2014, 75, 982-990.                          | 1.3  | 85        |
| 51 | Clinically meaningful biomarkers for psychosis: A systematic and quantitative review. Neuroscience and Biobehavioral Reviews, 2014, 45, 134-141.  | 6.1  | 87        |
| 52 | Polypharmacy: the good, the bad and the ugly. International Journal of Neuropsychopharmacology, 2014, 17, 981.  | 2.1  | 0         |
| 53 | The Enduring Centrality of Dopamine in the Pathophysiology of Schizophrenia. , 2014, , 151-152.   |      | 0         |
| 54 | Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. Human Brain Mapping, 2013, 34, 272-282.   | 3.6  | 97        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory. <i>Psychopharmacology</i> , 2013, 227, 221-229.   | 3.1 | 49        |
| 56 | Integrating mobile-phone based assessment for psychosis into people's everyday lives and clinical care: a qualitative study. <i>BMC Psychiatry</i> , 2013, 13, 34.   | 2.6 | 130       |
| 57 | Clinical trials for negative symptoms – Emerging directions and unresolved issues. <i>Schizophrenia Research</i> , 2013, 150, 327.   | 2.0 | 8         |
| 58 | Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 328-333.   | 2.0 | 46        |
| 59 | Detecting improvements in acute psychotic symptoms using experience sampling methodology. <i>Psychiatry Research</i> , 2013, 210, 82-88.   | 3.3 | 36        |
| 60 | Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. <i>Journal of Psychopharmacology</i> , 2013, 27, 19-27.   | 4.0 | 373       |
| 61 | Treating impaired cognition in schizophrenia: The case for combining cognitive-enhancing drugs with cognitive remediation. <i>European Neuropsychopharmacology</i> , 2013, 23, 790-798.  | 0.7 | 23        |
| 62 | Negative symptoms in schizophrenia – the remarkable impact of inclusion definitions in clinical trials and their consequences. <i>Schizophrenia Research</i> , 2013, 150, 334-338.   | 2.0 | 59        |
| 63 | Establishing Test-Retest Reliability of an Adapted [ <sup>18</sup> F]Fallypride Imaging Protocol in Older People. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1098-1103.  | 4.3 | 18        |
| 64 | Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970–2010. <i>American Journal of Psychiatry</i> , 2013, 170, 1335-1344.   | 7.2 | 112       |
| 65 | Microvascular Abnormality in Schizophrenia as Shown by Retinal Imaging. <i>American Journal of Psychiatry</i> , 2013, 170, 1451-1459.  | 7.2 | 95        |
| 66 | Olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 329-335.   | 1.4 | 56        |
| 67 | A Comparison of Two Delivery Modalities of a Mobile Phone-Based Assessment for Serious Mental Illness: Native Smartphone Application vs Text-Messaging Only Implementations. <i>Journal of Medical Internet Research</i> , 2013, 15, e60.                | 4.3 | 128       |
| 68 | Molecular imaging as a guide for the treatment of central nervous system disorders. <i>Dialogues in Clinical Neuroscience</i> , 2013, 15, 315-328.   | 3.7 | 18        |
| 69 | Aminergic Hypothesis for Schizophrenia. , 2013, , 1-6.   |     | 0         |
| 70 | Jumping to conclusions, a lack of belief flexibility and delusional conviction in psychosis: A longitudinal investigation of the structure, frequency, and relatedness of reasoning biases.. <i>Journal of Abnormal Psychology</i> , 2012, 121, 129-139. | 1.9 | 123       |
| 71 | Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001326.                            | 8.4 | 110       |
| 72 | Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 95-99.  | 1.4 | 22        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. <i>British Journal of Psychiatry</i> , 2012, 201, 481-485.  | 2.8  | 280       |
| 74 | Predicting Brain Occupancy from Plasma Levels using PET: Superiority of Combining Pharmacokinetics with Pharmacodynamics while Modeling the Relationship. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 759-768. | 4.3  | 28        |
| 75 | Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia. <i>American Journal of Psychiatry</i> , 2012, 169, 1203-1210.   | 7.2  | 291       |
| 76 | The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment. <i>Archives of General Psychiatry</i> , 2012, 69, 776-86.  | 12.3 | 769       |
| 77 | Improvement of Brain Reward Abnormalities by Antipsychotic Monotherapy in Schizophrenia. <i>Archives of General Psychiatry</i> , 2012, 69, 1195.  | 12.3 | 137       |
| 78 | Contrasting Effects of Haloperidol and Lithium on Rodent Brain Structure: A Magnetic Resonance Imaging Study with Postmortem Confirmation. <i>Biological Psychiatry</i> , 2012, 71, 855-863.  | 1.3  | 113       |
| 79 | Alterations of the Brain Reward System in Antipsychotic Naïve Schizophrenia Patients. <i>Biological Psychiatry</i> , 2012, 71, 898-905.   | 1.3  | 197       |
| 80 | Reply to: Lithium and the Expanding Brain. <i>Biological Psychiatry</i> , 2012, 72, e19.  | 1.3  | 0         |
| 81 | Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. <i>Schizophrenia Research</i> , 2012, 137, 147-150.   | 2.0  | 305       |
| 82 | Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?. <i>Molecular Psychiatry</i> , 2012, 17, 1174-1179.   | 7.9  | 883       |
| 83 | Role of Dopamine D2 Receptors for Antipsychotic Activity. <i>Handbook of Experimental Pharmacology</i> , 2012, , 27-52.   | 1.8  | 106       |
| 84 | The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. <i>BMC Psychiatry</i> , 2012, 12, 172.  | 2.6  | 161       |
| 85 | Effect of Chronic Antipsychotic Treatment on Brain Structure: A Serial Magnetic Resonance Imaging Study with Ex Vivo and Postmortem Confirmation. <i>Biological Psychiatry</i> , 2011, 69, 936-944.                                 | 1.3  | 166       |
| 86 | Exploring the Neural Correlates of Delusions of Reference. <i>Biological Psychiatry</i> , 2011, 70, 1127-1133.  | 1.3  | 57        |
| 87 | Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza. <i>Psiquiatria Biologica</i> , 2011, 18, 55-67.  | 0.1  | 2         |
| 88 | What Kraepelin might say about schizophrenia: Just the facts. <i>Schizophrenia Research</i> , 2011, 128, 1-2.   | 2.0  | 5         |
| 89 | Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. <i>Schizophrenia Research</i> , 2011, 130, 11-19.               | 2.0  | 34        |
| 90 | Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. <i>Schizophrenia Research</i> , 2011, 131, 63-68.                            | 2.0  | 78        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 91  | The evolution of antipsychotic switch and polypharmacy in natural practice – A longitudinal perspective. <i>Schizophrenia Research</i> , 2011, 130, 40-46.  | 2.0  | 57        |
| 92  | Haloperidol modulates noradrenergic responses to aversive stimulation depending on treatment duration. <i>Behavioural Brain Research</i> , 2011, 221, 311-313.  | 2.2  | 11        |
| 93  | Disruption of Frontal Theta Coherence by $\delta^9$ -Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms. <i>Neuropsychopharmacology</i> , 2011, 36, 827-836.                         | 5.4  | 74        |
| 94  | Grand challenges in global mental health. <i>Nature</i> , 2011, 475, 27-30.   | 27.8 | 1,654     |
| 95  | Relationship Between Daily Dose, Plasma Concentrations, Dopamine Receptor Occupancy, and Clinical Response to Quetiapine. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1108-1123.                | 2.2  | 39        |
| 96  | Aberrant Effective Connectivity in Schizophrenia Patients during Appetitive Conditioning. <i>Frontiers in Human Neuroscience</i> , 2011, 4, 239.  | 2.0  | 39        |
| 97  | Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 1327-1339.        | 2.1  | 46        |
| 98  | Calculating Occupancy when One does not have Baseline: A Comparison of Different Options. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1760-1767.                                 | 4.3  | 8         |
| 99  | The use of healthy volunteers instead of patients to inform drug dosing studies: a [ $^{11}$ C]raclopride PET study. <i>Psychopharmacology</i> , 2011, 217, 515-523.                                  | 3.1  | 12        |
| 100 | Effects of aging on $5\alpha$ -HT $_{2A}$ binding: a HRRT PET study with and without partial volume corrections. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1300-1308.          | 2.7  | 26        |
| 101 | Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies. <i>Human Psychopharmacology</i> , 2011, 26, 282-290. | 1.5  | 12        |
| 102 | Looking for a –biological test– to diagnose –schizophrenia– are we chasing red herrings?. <i>World Psychiatry</i> , 2011, 10, 32-32.  | 10.4 | 16        |
| 103 | Does intravenous $\delta^9$ -tetrahydrocannabinol increase dopamine release? A SPET study. <i>Journal of Psychopharmacology</i> , 2011, 25, 1462-1468.  | 4.0  | 84        |
| 104 | Partial agonists in schizophrenia – why some work and others do not: insights from preclinical animal models. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 1165-1178.          | 2.1  | 24        |
| 105 | How change comes: translating biological research into care. <i>The Psychiatrist</i> , 2011, 35, 321-324.   | 0.3  | 1         |
| 106 | An Algorithm-Based Approach to First-Episode Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1439-1444.  | 2.2  | 186       |
| 107 | –Extended– Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1042-1048.   | 2.2  | 58        |
| 108 | Early Onset of Antipsychotic Action in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 286-289.  | 1.4  | 10        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 109 | Do Antipsychotics Improve Reasoning Biases? A Review. <i>Psychosomatic Medicine</i> , 2010, 72, 681-693.   | 2.0  | 57        |
| 110 | Antipsychotic Dosing: How Much but also How Often?. <i>Schizophrenia Bulletin</i> , 2010, 36, 900-903.   | 4.3  | 60        |
| 111 | Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. <i>Journal of Psychiatric Research</i> , 2010, 44, 8-14.  | 3.1  | 27        |
| 112 | The effects of reality distortion syndrome on salient stimuli processing in patients with schizophrenia: An fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2010, 183, 93-98.                    | 1.8  | 6         |
| 113 | The neurobiology of schizophrenia: new leads and avenues for treatment. <i>Current Opinion in Neurobiology</i> , 2010, 20, 810-815.  | 4.2  | 24        |
| 114 | Dopamine-induced changes in neural network patterns supporting aversive conditioning. <i>Brain Research</i> , 2010, 1313, 143-161.   | 2.2  | 27        |
| 115 | Is desire for social relationships mediated by the serotonergic system in the prefrontal cortex? An [ <sup>18</sup> F]setoperone PET study. <i>Social Neuroscience</i> , 2010, 5, 375-383.               | 1.3  | 24        |
| 116 | Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia. <i>Neuropsychopharmacology</i> , 2010, 35, 581-590.                          | 5.4  | 165       |
| 117 | The Antipsychotics Olanzapine, Risperidone, Clozapine, and Haloperidol Are D2-Selective Ex Vivo but Not In Vitro. <i>Neuropsychopharmacology</i> , 2010, 35, 1826-1835.                                  | 5.4  | 57        |
| 118 | Blockade of [ <sup>11</sup> C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 273.                | 2.1  | 63        |
| 119 | Specific and Generalized Neuropsychological Deficits: A Comparison of Patients With Various First-Episode Psychosis Presentations. <i>American Journal of Psychiatry</i> , 2010, 167, 78-85.             | 7.2  | 175       |
| 120 | Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia. <i>Schizophrenia Research</i> , 2010, 118, 176-182. | 2.0  | 22        |
| 121 | Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization. <i>Molecular Brain</i> , 2010, 3, 25.      | 2.6  | 79        |
| 122 | Opposite Effects of <sup>11</sup> -9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology. <i>Neuropsychopharmacology</i> , 2010, 35, 764-774.                               | 5.4  | 595       |
| 123 | Dopamine Receptors and the Treatment of Schizophrenia. <i>Receptors</i> , 2010, , 431-477.   | 0.2  | 7         |
| 124 | A Systematic Review of Aripiprazole's Dose, Plasma Concentration, Receptor Occupancy, and Response. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1447-1456.   | 2.2  | 93        |
| 125 | The acute effects of synthetic intravenous <sup>11</sup> -9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. <i>Psychological Medicine</i> , 2009, 39, 1607.                           | 4.5  | 259       |
| 126 | The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors. <i>Archives of General Psychiatry</i> , 2009, 66, 606.   | 12.3 | 97        |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 127 | Decreased binding of the D3 dopamine receptor-preferring ligand [ <sup>11</sup> C]-(+)-PHNO in drug-naive Parkinson's disease. <i>Brain</i> , 2009, 132, 1366-1375.   | 7.6  | 93        |
| 128 | The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 715. | 2.1  | 52        |
| 129 | D2-Receptor Upregulation is Dependent upon Temporal Course of D2-Occupancy: A Longitudinal [ <sup>11</sup> C]-Raclopride PET Study in Cats. <i>Neuropsychopharmacology</i> , 2009, 34, 662-671.   | 5.4  | 78        |
| 130 | The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [ <sup>11</sup> C]-(+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2009, 34, 1078-1086.   | 5.4  | 109       |
| 131 | Gestational treatment with methylazoxymethanol (MAM) that disrupts hippocampal-dependent memory does not alter behavioural response to cocaine. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 93, 382-390.                        | 2.9  | 13        |
| 132 | Dopaminergic activity in depressed smokers: A positron emission tomography study. <i>Synapse</i> , 2009, 63, 681-689.   | 1.2  | 50        |
| 133 | Ex vivo [ <sup>11</sup> C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D <sub>2</sub> receptor in vitro. <i>Synapse</i> , 2009, 63, 998-1009.   | 1.2  | 23        |
| 134 | The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway. <i>Schizophrenia Bulletin</i> , 2009, 35, 549-562.   | 4.3  | 2,149     |
| 135 | Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion. <i>European Neuropsychopharmacology</i> , 2009, 19, 416-430.  | 0.7  | 21        |
| 136 | Advantages and disadvantages of combination treatment with antipsychotics. <i>European Neuropsychopharmacology</i> , 2009, 19, 520-532.   | 0.7  | 125       |
| 137 | BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans. <i>European Neuropsychopharmacology</i> , 2009, 19, 841-850.   | 0.7  | 10        |
| 138 | Schizophrenia. <i>Lancet, The</i> , 2009, 374, 635-645.   | 13.7 | 1,820     |
| 139 | Sensitivity of Older Patients to Antipsychotic Motor Side Effects: A PET Study Examining Potential Mechanisms. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 255-263.   | 1.2  | 58        |
| 140 | D2 Receptor Blockade by Risperidone Correlates With Attention Deficits in Late-Life Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 571-575.   | 1.4  | 41        |
| 141 | Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging. <i>Current Pharmaceutical Design</i> , 2009, 15, 2550-2559.   | 1.9  | 213       |
| 142 | Increased Antipsychotic Sensitivity in Elderly Patients. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 397-405.   | 2.2  | 104       |
| 143 | 10.3 How Antipsychotics Work: Linking Receptors to Response. , 2009, , 540-557.   |      | 0         |
| 144 | The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist. <i>Psychopharmacology</i> , 2008, 199, 275-289.   | 3.1  | 53        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. <i>Human Brain Mapping</i> , 2008, 29, 400-410.  | 3.6 | 95        |
| 146 | Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?. <i>Schizophrenia Bulletin</i> , 2008, 34, 1130-1144.   | 4.3 | 88        |
| 147 | Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: Contrast with haloperidol and chlordiazepoxide. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 551-562. | 2.9 | 46        |
| 148 | New and old antipsychotics: what "effectiveness" trials tell us. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 443-446.  | 0.2 | 1         |
| 149 | "Jumping to conclusions" and delusions in psychosis: Relationship and response to treatment. <i>Schizophrenia Research</i> , 2008, 98, 225-231.   | 2.0 | 97        |
| 150 | Attribution style as a factor in psychosis and symptom resolution. <i>Schizophrenia Research</i> , 2008, 104, 220-227.  | 2.0 | 30        |
| 151 | Disaster mental health in Asia and the Asian Journal of Psychiatry. <i>Asian Journal of Psychiatry</i> , 2008, 1, 5-6.  | 2.0 | 2         |
| 152 | Less Is More: Antipsychotic Drug Effects Are Greater with Transient Rather Than Continuous Delivery. <i>Biological Psychiatry</i> , 2008, 64, 145-152.  | 1.3 | 104       |
| 153 | Dopamine D2 receptor radiotracers [11C](+)-PHNO and [3H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. <i>Nuclear Medicine and Biology</i> , 2008, 35, 11-17.                       | 0.6 | 47        |
| 154 | A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory. <i>Behavioural Brain Research</i> , 2008, 189, 170-179.                                       | 2.2 | 55        |
| 155 | Amisulpride the "atypical" atypical antipsychotic " Comparison to haloperidol, risperidone and clozapine. <i>Schizophrenia Research</i> , 2008, 105, 224-235.   | 2.0 | 64        |
| 156 | Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. <i>Schizophrenia Research</i> , 2008, 102, 241-248.   | 2.0 | 44        |
| 157 | Emerging drugs for schizophrenia. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 479-495.  | 2.4 | 45        |
| 158 | Variations of rest "Activity rhythm and sleep "Awake in schizophrenic patients versus healthy subjects: An actigraphic comparative study. <i>Biological Rhythm Research</i> , 2008, 39, 69-78.                          | 0.9 | 18        |
| 159 | The Formation of Abnormal Associations in Schizophrenia: Neural and Behavioral Evidence. <i>Neuropsychopharmacology</i> , 2008, 33, 473-479.  | 5.4 | 195       |
| 160 | First Human Evidence of d-Amphetamine Induced Displacement of a D2/3 Agonist Radioligand: A [11C]-(+)-PHNO Positron Emission Tomography Study. <i>Neuropsychopharmacology</i> , 2008, 33, 279-289.                      | 5.4 | 109       |
| 161 | D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2008, 33, 298-304.                           | 5.4 | 65        |
| 162 | Quetiapine Extended-Release Versus Immediate-Release Formulation. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 81-86.  | 2.2 | 40        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1281-1286.                                      | 2.2 | 46        |
| 164 | Adverse Subjective Experience With Antipsychotics and Its Relationship to Striatal and Extrastriatal D <sub>2</sub> Receptors: a PET Study in Schizophrenia. <i>American Journal of Psychiatry</i> , 2007, 164, 630-637.                        | 7.2 | 141       |
| 165 | “Breakthrough” Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time. <i>Journal of Neuroscience</i> , 2007, 27, 2979-2986.   | 3.6 | 235       |
| 166 | Linking Animal Models of Psychosis to Computational Models of Dopamine Function. <i>Neuropsychopharmacology</i> , 2007, 32, 54-66.  | 5.4 | 35        |
| 167 | Blockade of 5-HT <sub>2a</sub> Receptors Reduces Haloperidol-Induced Attenuation of Reward. <i>Neuropsychopharmacology</i> , 2007, 32, 551-561.   | 5.4 | 36        |
| 168 | Time Course of the Antipsychotic Effect and the Underlying Behavioral Mechanisms. <i>Neuropsychopharmacology</i> , 2007, 32, 263-272.   | 5.4 | 65        |
| 169 | A Sensitizing Regimen of Amphetamine Impairs Visual Attention in the 5-Choice Serial Reaction Time Test: Reversal by a D1 Receptor Agonist Injected into the Medial Prefrontal Cortex. <i>Neuropsychopharmacology</i> , 2007, 32, 1122-1132.    | 5.4 | 69        |
| 170 | Evaluation of N-Desmethylclozapine as a Potential Antipsychotic—Preclinical Studies. <i>Neuropsychopharmacology</i> , 2007, 32, 1540-1549.  | 5.4 | 47        |
| 171 | Differential Effects of Aripiprazole on D <sub>2</sub> , 5-HT <sub>2</sub> , and 5-HT <sub>1A</sub> Receptor Occupancy in Patients With Schizophrenia: A Triple Tracer PET Study. <i>American Journal of Psychiatry</i> , 2007, 164, 1411-1417. | 7.2 | 235       |
| 172 | Gestational Methylazoxymethanol Acetate Treatment Impairs Select Cognitive Functions: Parallels to Schizophrenia. <i>Neuropsychopharmacology</i> , 2007, 32, 483-492.   | 5.4 | 104       |
| 173 | Striatal Vs Extrastriatal Dopamine D2 Receptors in Antipsychotic Response—A Double-Blind PET Study in Schizophrenia. <i>Neuropsychopharmacology</i> , 2007, 32, 1209-1215.  | 5.4 | 118       |
| 174 | The effect of antipsychotic treatment on Theory of Mind. <i>Psychological Medicine</i> , 2007, 37, 595.   | 4.5 | 64        |
| 175 | Early Use of Clozapine for Poorly Responding First-Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 369-373.  | 1.4 | 82        |
| 176 | Amoxapine as an Antipsychotic. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 575-581.   | 1.4 | 17        |
| 177 | The amphetamine-induced sensitized state as a model of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1556-1571.  | 4.8 | 186       |
| 178 | A Positron Emission Tomography Study of 5-Hydroxytryptamine-1A Receptors in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 888-898.   | 1.2 | 45        |
| 179 | Temporal Difference Modeling of the Blood-Oxygen Level Dependent Response During Aversive Conditioning in Humans: Effects of Dopaminergic Modulation. <i>Biological Psychiatry</i> , 2007, 62, 765-772.   | 1.3 | 138       |
| 180 | Separate brain regions code for salience vs. valence during reward prediction in humans. <i>Human Brain Mapping</i> , 2007, 28, 294-302.  | 3.6 | 163       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Quantification of l-stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescence detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 850, 544-547.  | 2.3 | 3         |
| 182 | Increased dopamine D2High receptors in amphetamine-sensitized rats, measured by the agonist [3H](+)PHNO. <i>Synapse</i> , 2007, 61, 263-267.  | 1.2 | 49        |
| 183 | Positron Emission Tomography Quantification of [11C]-(+)-PHNO Binding in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 857-871.   | 4.3 | 88        |
| 184 | Dopamine, prediction error and associative learning: A model-based account. <i>Network: Computation in Neural Systems</i> , 2006, 17, 61-84.  | 3.6 | 62        |
| 185 | High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [11C]-(+)-PHNO. <i>Biological Psychiatry</i> , 2006, 59, 389-394.   | 1.3 | 129       |
| 186 | A model of anticholinergic activity of atypical antipsychotic medications. <i>Schizophrenia Research</i> , 2006, 88, 63-72.   | 2.0 | 121       |
| 187 | The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2006, 88, 111-118.   | 2.0 | 52        |
| 188 | In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. <i>Synapse</i> , 2006, 60, 172-183.   | 1.2 | 24        |
| 189 | Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. <i>Synapse</i> , 2006, 60, 205-211.  | 1.2 | 64        |
| 190 | Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. <i>Journal of Neurochemistry</i> , 2006, 97, 1089-1103.   | 3.9 | 145       |
| 191 | How antipsychotics workâ€”From receptors to reality. <i>NeuroRx</i> , 2006, 3, 10-21.   | 6.0 | 77        |
| 192 | An automated method for the extraction of regional data from PET images. <i>Psychiatry Research - Neuroimaging</i> , 2006, 147, 79-89.  | 1.8 | 148       |
| 193 | A PET Study Evaluating Dopamine D2Receptor Occupancy for Long-Acting Injectable Risperidone. <i>American Journal of Psychiatry</i> , 2006, 163, 396-401.  | 7.2 | 132       |
| 194 | Dissociation between In Vivo Occupancy and Functional Antagonism of Dopamine D2 Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models. <i>Neuropsychopharmacology</i> , 2006, 31, 1854-1863.   | 5.4 | 194       |
| 195 | The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 810-818. | 2.5 | 75        |
| 196 | The "delayed onset" of antipsychotic action—an idea whose time has come and gone. <i>Journal of Psychiatry and Neuroscience</i> , 2006, 31, 93-100.   | 2.4 | 84        |
| 197 | "Extended" Antipsychotic Dosing. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 611-613.   | 1.4 | 29        |
| 198 | Treatment Response to Olanzapine and Haloperidol and its Association with Dopamine D <sub>2</sub> Receptor Occupancy in First-Episode Psychosis. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 462-469.   | 1.9 | 24        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. <i>Psychopharmacology</i> , 2005, 181, 600-610.  | 3.1 | 22        |
| 200 | Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. <i>Psychopharmacology</i> , 2005, 183, 190-200.   | 3.1 | 113       |
| 201 | Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. <i>Psychopharmacology</i> , 2005, 180, 366-376.   | 3.1 | 74        |
| 202 | Amoxapine as an Atypical Antipsychotic: A Comparative Study Vs Risperidone. <i>Neuropsychopharmacology</i> , 2005, 30, 2236-2244.  | 5.4 | 28        |
| 203 | Dopamine Specifically Inhibits Forebrain Neural Stem Cell Proliferation, Suggesting a Novel Effect of Antipsychotic Drugs. <i>Journal of Neuroscience</i> , 2005, 25, 5815-5823.   | 3.6 | 188       |
| 204 | A Computational Model of the Functional Role of the Ventral-Striatal D2 Receptor in the Expression of Previously Acquired Behaviors. <i>Neural Computation</i> , 2005, 17, 361-395.  | 2.2 | 30        |
| 205 | Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment. <i>American Journal of Psychiatry</i> , 2005, 162, 939-946.  | 7.2 | 193       |
| 206 | Radiosynthesis and Evaluation of [11C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4153-4160. | 6.4 | 218       |
| 207 | How antipsychotics work: The patients' perspective. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 859-864.   | 4.8 | 30        |
| 208 | Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. <i>Biological Psychiatry</i> , 2005, 57, 406-411.   | 1.3 | 41        |
| 209 | A putative animal model of the "prodromal" state of schizophrenia. <i>Biological Psychiatry</i> , 2005, 57, 586-593.   | 1.3 | 63        |
| 210 | Effects of chronic typical and atypical antipsychotic drug treatment on maternal behavior in rats. <i>Schizophrenia Research</i> , 2005, 75, 325-336.  | 2.0 | 30        |
| 211 | From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis. <i>Schizophrenia Research</i> , 2005, 79, 59-68.  | 2.0 | 433       |
| 212 | Contrasting loxapine to its isomer isoloxapine—the critical role of in vivo D2 blockade in determining atypicality. <i>Schizophrenia Research</i> , 2005, 77, 189-199.   | 2.0 | 12        |
| 213 | PET imaging of DA neurotransmission using agonist versus antagonist radiotracers. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S715-S715.  | 4.3 | 0         |
| 214 | The D2-agonist radiotracer [11C]-(+)-PHNO shows a marked increase in sensitivity to amphetamine challenges when compared to [11C]raclopride in the cat brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S611-S611.  | 4.3 | 0         |
| 215 | Evaluation of [11C]-(+)-PHNO as an agonist radiotracer for imaging high-affinity dopamine D2 receptors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S594-S594.  | 4.3 | 0         |
| 216 | A Model of Antipsychotic Action in Conditioned Avoidance: A Computational Approach. <i>Neuropsychopharmacology</i> , 2004, 29, 1040-1049.  | 5.4 | 36        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Equivalent Occupancy of Dopamine D <sub>1</sub> and D <sub>2</sub> Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics. <i>American Journal of Psychiatry</i> , 2004, 161, 1620-1625.                      | 7.2 | 146       |
| 218 | Relation between cortical dopamine D2 receptor occupancy and suppression of conditioned avoidance response in non-human primate. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 330-332.                                  | 1.8 | 5         |
| 219 | Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 78, 811-819.  | 2.9 | 40        |
| 220 | EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. <i>Psychopharmacology</i> , 2004, 175, 382-388.  | 3.1 | 16        |
| 221 | Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. <i>Synapse</i> , 2004, 51, 27-31.   | 1.2 | 55        |
| 222 | Quantitative validation of an intracerebral $\alpha$ -sensitive microprobe system to determine in vivo drug-induced receptor occupancy using [11C]raclopride in rats. <i>Synapse</i> , 2004, 52, 89-99.                             | 1.2 | 24        |
| 223 | Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine. <i>Synapse</i> , 2004, 52, 153-162.  | 1.2 | 11        |
| 224 | Amphetamine pretreatment induces a change in both D <sub>2</sub> -Receptor density and apparent affinity: a [11C]raclopride positron emission tomography study in cats. <i>Biological Psychiatry</i> , 2004, 55, 1188-1194.         | 1.3 | 40        |
| 225 | Effects of typical and atypical antipsychotic drugs on maternal behavior in postpartum female rats. <i>Schizophrenia Research</i> , 2004, 70, 69-80.  | 2.0 | 52        |
| 226 | How antipsychotics become anti- $\alpha$ -psychotic <sup>TM</sup> $\alpha$ from dopamine to salience to psychosis. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 402-406.   | 8.7 | 108       |
| 227 | Brain Activation During Affective Visual Cues in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 450-452.  | 1.4 | 7         |
| 228 | A PET Study of Dopamine D <sub>2</sub> and Serotonin 5-HT <sub>2</sub> Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone. <i>American Journal of Psychiatry</i> , 2004, 161, 818-825. | 7.2 | 188       |
| 229 | The newer antipsychotics: underlying mechanisms and the new clinical realities. <i>Current Opinion in Psychiatry</i> , 2004, 17, 115-121.   | 6.3 | 10        |
| 230 | The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. <i>Psychopharmacology</i> , 2003, 165, 166-171.  | 3.1 | 58        |
| 231 | Effect of antipsychotics on cortical inhibition using transcranial magnetic stimulation. <i>Psychopharmacology</i> , 2003, 170, 255-262.  | 3.1 | 43        |
| 232 | Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 74, 425-432.   | 2.9 | 76        |
| 233 | Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors. <i>Synapse</i> , 2003, 50, 35-40.   | 1.2 | 69        |
| 234 | Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study. <i>Schizophrenia Research</i> , 2003, 59, 35-39.  | 2.0 | 18        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 235 | Apathy in schizophrenia: clinical correlates and association with functional outcome. <i>Schizophrenia Research</i> , 2003, 63, 79-88.   | 2.0  | 106       |
| 236 | Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. <i>Schizophrenia Research</i> , 2003, 64, 103-114.   | 2.0  | 86        |
| 237 | Half a century of antipsychotics and still a central role for dopamine D2 receptors. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 1081-1090.  | 4.8  | 520       |
| 238 | Direct Activation of the Ventral Striatum in Anticipation of Aversive Stimuli. <i>Neuron</i> , 2003, 40, 1251-1257.  | 8.1  | 405       |
| 239 | Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 625-631.                              | 2.5  | 431       |
| 240 | Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia. <i>American Journal of Psychiatry</i> , 2003, 160, 13-23.  | 7.2  | 2,311     |
| 241 | Delayed-Onset Hypothesis of Antipsychotic Action. <i>Archives of General Psychiatry</i> , 2003, 60, 1228.  | 12.3 | 398       |
| 242 | Differential Effects of Within-Day Continuous Vs Transient Dopamine D2 Receptor Occupancy in the Development of Vacuous Chewing Movements (VCMs) in Rats. <i>Neuropsychopharmacology</i> , 2003, 28, 1433-1439.  | 5.4  | 51        |
| 243 | From Dopamine to Psychosis: A Computational Approach. <i>Lecture Notes in Computer Science</i> , 2003, , 1115-1121.  | 1.3  | 0         |
| 244 | Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. <i>Journal of Psychiatry and Neuroscience</i> , 2003, 28, 293-9.  | 2.4  | 18        |
| 245 | Evidence for Impaired Cortical Inhibition in Schizophrenia Using Transcranial Magnetic Stimulation. <i>Archives of General Psychiatry</i> , 2002, 59, 347.   | 12.3 | 256       |
| 246 | Review: amisulpride is effective and safe for schizophrenia. <i>Evidence-Based Mental Health</i> , 2002, 5, 85-85.   | 4.5  | 0         |
| 247 | Elevation of Prolactin Levels by Atypical Antipsychotics. <i>American Journal of Psychiatry</i> , 2002, 159, 133-135.  | 7.2  | 199       |
| 248 | The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 1129-1134. | 2.5  | 148       |
| 249 | Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. <i>NeuroReport</i> , 2002, 13, 831-835.   | 1.2  | 29        |
| 250 | Clozapine can induce high dopamine D2 receptor occupancy in vivo. <i>Psychopharmacology</i> , 2002, 160, 107-112.  | 3.1  | 21        |
| 251 | Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. <i>Synapse</i> , 2002, 46, 235-239.  | 1.2  | 73        |
| 252 | NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia. <i>Molecular Psychiatry</i> , 2002, 7, 837-844.  | 7.9  | 416       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 253 | Brain Serotonin 5-HT <sub>1A</sub> Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [ <sup>11</sup> C]WAY-100635. <i>Archives of General Psychiatry</i> , 2002, 59, 514.                        | 12.3 | 130       |
| 254 | Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D <sub>2</sub> receptor. <i>Biological Psychiatry</i> , 2001, 49, 954-955.   | 1.3  | 50        |
| 255 | Dopamine D <sub>2</sub> receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. <i>Biological Psychiatry</i> , 2001, 50, 873-883.  | 1.3  | 339       |
| 256 | Comment on "ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D <sub>2</sub> receptor" Reply. <i>Biological Psychiatry</i> , 2001, 50, 555-556.                                      | 1.3  | 5         |
| 257 | Choosing the Right Dose of Antipsychotics in Schizophrenia. <i>CNS Drugs</i> , 2001, 15, 671-678.   | 5.9  | 74        |
| 258 | Atypical Antipsychotics: New Directions and New Challenges in the Treatment of Schizophrenia. <i>Annual Review of Medicine</i> , 2001, 52, 503-517.   | 12.2 | 293       |
| 259 | The Role of Neuroimaging in Development of and Treatment With Antipsychotics. <i>Journal of Pharmacy Practice</i> , 2001, 14, 332-340.  | 1.0  | 0         |
| 260 | Amoxapine Shows an Antipsychotic Effect but Worsens Motor Function in Patients with Parkinson's Disease and Psychosis. <i>Clinical Neuropharmacology</i> , 2001, 24, 242-244.   | 0.7  | 16        |
| 261 | Increased Dopamine D <sub>2</sub> Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to Clozapine. <i>American Journal of Psychiatry</i> , 2001, 158, 311-314.                           | 7.2  | 99        |
| 262 | Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo. <i>Psychopharmacology</i> , 2001, 157, 168-171.   | 3.1  | 27        |
| 263 | Dopamine D <sub>2</sub> Receptor Occupancy Is a Common Mechanism Underlying Animal Models of Antipsychotics and Their Clinical Effects. <i>Neuropsychopharmacology</i> , 2001, 25, 633-641.                                   | 5.4  | 214       |
| 264 | Does Fast Dissociation From the Dopamine D <sub>2</sub> Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis. <i>American Journal of Psychiatry</i> , 2001, 158, 360-369.                                | 7.2  | 1,131     |
| 265 | Inverse Relationship Between Serotonin 5-HT <sub>1A</sub> Receptor Binding and Anxiety: A [ <sup>11</sup> C]WAY-100635 PET Investigation in Healthy Volunteers. <i>American Journal of Psychiatry</i> , 2001, 158, 1326-1328. | 7.2  | 134       |
| 266 | The Effect of Paroxetine on 5-HT <sub>2A</sub> Receptors in Depression: An [ <sup>18</sup> F]Setoperone PET Imaging Study. <i>American Journal of Psychiatry</i> , 2001, 158, 78-85.  | 7.2  | 222       |
| 267 | A Positron Emission Tomography Study of Silent and Oral Single Word Reading in Stuttering and Nonstuttering Adults. <i>Journal of Speech, Language, and Hearing Research</i> , 2000, 43, 1038-1053.                           | 1.6  | 141       |
| 268 | Are Animal Studies of Antipsychotics Appropriately Dosed?: Lessons from the Bedside to the Bench. <i>Canadian Journal of Psychiatry</i> , 2000, 45, 241-246.  | 1.9  | 70        |
| 269 | Dopamine D <sub>2</sub> Receptor Blockade by Haloperidol 3H-Raclopride Reveals Much Higher Occupancy than EEDQ. <i>Neuropsychopharmacology</i> , 2000, 23, 595-598.   | 5.4  | 21        |
| 270 | Dopamine D <sub>2</sub> receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. <i>Psychopharmacology</i> , 2000, 150, 422-429.   | 3.1  | 153       |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 271 | Increased dopamine D <sub>2</sub> receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. <i>Psychopharmacology</i> , 2000, 152, 174-180.                                      | 3.1  | 249       |
| 272 | Relationship Between Dopamine D <sub>2</sub> Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia. <i>American Journal of Psychiatry</i> , 2000, 157, 514-520.      | 7.2  | 982       |
| 273 | Schizophrenia: More dopamine, more D <sub>2</sub> receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 7673-7675.   | 7.1  | 241       |
| 274 | The Effect of Divided Attention on Encoding and Retrieval in Episodic Memory Revealed by Positron Emission Tomography. <i>Journal of Cognitive Neuroscience</i> , 2000, 12, 267-280.                                   | 2.3  | 119       |
| 275 | The Effects of Divided Attention on Encoding- and Retrieval-Related Brain Activity: A PET Study of Younger and Older Adults. <i>Journal of Cognitive Neuroscience</i> , 2000, 12, 775-792.                             | 2.3  | 208       |
| 276 | Antipsychoticlike effects of amoxapine, without catalepsy, using the prepulse inhibition of the acoustic startle reflex test in rats. <i>Biological Psychiatry</i> , 2000, 47, 670-676.                                | 1.3  | 11        |
| 277 | A voxel-by-voxel analysis of [ <sup>18</sup> F]setoperone PET data shows no substantial serotonin 5-HT <sub>2A</sub> receptor changes in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2000, 99, 123-135. | 1.8  | 49        |
| 278 | Receptor Occupancy by Antipsychotics – Concepts and Findings. <i>Handbooks of Pharmacology and Toxicology</i> , 2000, , 163-176.   | 0.1  | 8         |
| 279 | Relationship between central and peripheral serotonin 5-HT <sub>2A</sub> receptors: a positron emission tomography study in healthy individuals. <i>Neuroscience Letters</i> , 1999, 261, 139-142.                     | 2.1  | 15        |
| 280 | Is amoxapine an atypical antipsychotic? positron-emission tomography investigation of its dopamine <sub>2</sub> and serotonin <sub>2</sub> occupancy. <i>Biological Psychiatry</i> , 1999, 45, 1217-1220.              | 1.3  | 70        |
| 281 | Serotonin 5-HT <sub>2</sub> Receptors in Schizophrenia: A PET Study Using [ <sup>18</sup> F]Setoperone in Neuroleptic-Naive Patients and Normal Subjects. <i>American Journal of Psychiatry</i> , 1999, 156, 72-78.    | 7.2  | 108       |
| 282 | Mapping Neural Interactivity onto Regional Activity: An Analysis of Semantic Processing and Response Mode Interactions. <i>NeuroImage</i> , 1998, 7, 244-254.  | 4.2  | 29        |
| 283 | Task-Independent Effect of Time on rCBF. <i>NeuroImage</i> , 1998, 7, 314-325.   | 4.2  | 36        |
| 284 | Neuroanatomical Correlates of Human Reasoning. <i>Journal of Cognitive Neuroscience</i> , 1998, 10, 293-302.   | 2.3  | 294       |
| 285 | Cerebral Gray Matter Volume Deficits in First Episode Psychosis. <i>Archives of General Psychiatry</i> , 1998, 55, 540.  | 12.3 | 133       |
| 286 | 5-HT <sub>2</sub> and D <sub>2</sub> Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation. <i>American Journal of Psychiatry</i> , 1998, 155, 921-928.   | 7.2  | 359       |
| 287 | Functional network differences in schizophrenia. <i>NeuroReport</i> , 1998, 9, 1697-1700.  | 1.2  | 55        |
| 288 | Pharmacotherapy of first-episode schizophrenia. <i>British Journal of Psychiatry</i> , 1998, 172, 66-70.   | 2.8  | 68        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 289 | New insights into schizophrenia from neuroimaging. <i>Current Opinion in Psychiatry</i> , 1998, 11, 33-37.   | 6.3 | 7         |
| 290 | The Relationship Between Risperidone Plasma Levels and Dopamine D (2) Occupancy. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 82-83.  | 1.4 | 23        |
| 291 | PET Evidence That Loxapine Is an Equipotent Blocker of 5-HT <sub>2</sub> and D <sub>2</sub> Receptors: Implications for the Therapeutics of Schizophrenia. <i>American Journal of Psychiatry</i> , 1997, 154, 1525-1529. | 7.2 | 92        |
| 292 | Reliability of a simple non-invasive method for the evaluation of 5-HT <sub>2</sub> receptors using [18F]-setoperone PET imaging. <i>Nuclear Medicine Communications</i> , 1997, 18, 395-399.                            | 1.1 | 31        |
| 293 | The seats of reason? An imaging study of deductive and inductive reasoning. <i>NeuroReport</i> , 1997, 8, 1305-1310.   | 1.2 | 281       |
| 294 | Cognitive Subtractions May Not Add Up: The Interaction between Semantic Processing and Response Mode. <i>NeuroImage</i> , 1997, 5, 229-239.  | 4.2 | 89        |
| 295 | Functional Neuroanatomy of Recall and Recognition: A PET Study of Episodic Memory. <i>Journal of Cognitive Neuroscience</i> , 1997, 9, 254-265.  | 2.3 | 214       |
| 296 | Age-Related Differences in Neural Activity during Memory Encoding and Retrieval: A Positron Emission Tomography Study. <i>Journal of Neuroscience</i> , 1997, 17, 391-400.   | 3.6 | 692       |
| 297 | The relationship between D <sub>2</sub> receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. <i>Psychopharmacology</i> , 1997, 131, 148-152.  | 3.1 | 118       |
| 298 | Neuromodulation of frontal and temporal cortex by intravenous d-fenfluramine: an [15O]H <sub>2</sub> O PET study in humans. <i>Neuroscience Letters</i> , 1996, 207, 25-28.  | 2.1 | 33        |
| 299 | The neural correlates of intentional learning of verbal materials: A PET study in humans. <i>Cognitive Brain Research</i> , 1996, 4, 243-249.  | 3.0 | 156       |
| 300 | Effects of self-generated sad mood on regional cerebral activity: A PET study in normal subjects. <i>Depression</i> , 1996, 4, 81-88.  | 0.6 | 58        |
| 301 | Dissociation of pathways for object and spatial vision: a PET study in humans. <i>NeuroReport</i> , 1995, 6, 1865-1868.  | 1.2 | 154       |
| 302 | Functional role of the prefrontal cortex in retrieval of memories: a PET study. <i>NeuroReport</i> , 1995, 6, 1880-1884.   | 1.2 | 303       |
| 303 | The D <sub>2</sub> dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study. <i>Life Sciences</i> , 1995, 57, PL103-PL107.  | 4.3 | 204       |
| 304 | Modulation of cortical neuronal activity by a serotonergic agent: a PET study in humans. <i>Brain Research</i> , 1994, 646, 292-294.   | 2.2 | 44        |
| 305 | Activation of specific cortical regions by apomorphine: an [15O]H <sub>2</sub> O PET study in humans. <i>Neuroscience Letters</i> , 1994, 176, 21-24.  | 2.1 | 33        |
| 306 | The role of the left prefrontal cortex in verbal processing. <i>NeuroReport</i> , 1994, 5, 2193-2196.  | 1.2 | 223       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 307 | Electroconvulsive shock increases tyrosine hydroxylase and neuropeptide Y gene expression in the locus coeruleus. <i>Molecular Brain Research</i> , 1993, 18, 121-126. | 2.3 | 18        |
| 308 | Role of the dopaminergic system in depression. <i>Biological Psychiatry</i> , 1992, 32, 1-17.  | 1.3 | 318       |
| 309 | Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. <i>Schizophrenia Research</i> , 1991, 6, 49-53.                      | 2.0 | 24        |
| 310 | Functional Neuroimaging in Psychiatry. , 0, , 167-193.   |     | 0         |
| 311 | Imaging of brain structure and function: relevance to psychiatric disorders. , 0, , 68-79.   |     | 0         |